HDAC inhibitors have been studied across numerous cancer types and have gained regulatory approval in the United States in relapsed / refractory (R/R) cutaneous- and peripheral- T-cell lymphoma and in combination with proteasome inhibitors in myeloma. The gene discussed is HDAC9; the disease is cancer.